四环医药(00460.HK) 公布,非全资附属公司轩竹生物(02575.HK) 自主研发的创新药安奈拉唑钠肠溶片(商品名安久卫)用于含安奈拉唑钠的铋剂四联疗法根除幽门螺杆菌的III期临床研究,近日已成功完成首例患者入组,标志着该项关键注册临床研究正式迈入实质性执行阶段。(ha/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-06-18 16:25。)AASTOCKS新闻
Source Link四环医药(00460.HK) 公布,非全资附属公司轩竹生物(02575.HK) 自主研发的创新药安奈拉唑钠肠溶片(商品名安久卫)用于含安奈拉唑钠的铋剂四联疗法根除幽门螺杆菌的III期临床研究,近日已成功完成首例患者入组,标志着该项关键注册临床研究正式迈入实质性执行阶段。(ha/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-06-18 16:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.